Welcome to our dedicated page for LB Pharmaceuticals news (Ticker: LBRX), a resource for investors and traders seeking the latest updates and insights on LB Pharmaceuticals stock.
LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (Nasdaq: LBRX) reported 3Q 2025 results and corporate updates on Nov 6, 2025. The company completed an upsized IPO of 21,850,000 shares at $15.00 raising $327.8M gross and held $314.5M cash, projected to fund operations into Q2 2028. LB-102 Phase 2 NOVA1 data showed dose-dependent cognitive effect sizes vs placebo of 0.26 (50 mg), 0.41 (75 mg) and 0.66 (100 mg). The company plans a Phase 3 acute schizophrenia trial (sample size increased from ~400 to ~460) starting in Q1 2026 with topline in H2 2027, and a potentially registrational Phase 2 bipolar depression trial starting Q1 2026 with topline in Q1 2028.
LB Pharmaceuticals (Nasdaq: LBRX) appointed James Rawls, Pharm.D. as Senior Vice President of Regulatory Affairs on October 14, 2025.
Dr. Rawls brings 25+ years of regulatory leadership, with experience at Novartis, Sunovion, Sumitomo Pharma America, and Boston Biodevelopment, and has contributed to multiple global regulatory filings and product approvals. The company said his expertise will support advancing LB-102 into a Phase 3 schizophrenia trial and a Phase 2 bipolar depression trial planned for 2026.
LB Pharmaceuticals (Nasdaq: LBRX) will present three posters at the 38th ECNP Congress (Amsterdam, Oct 11-14, 2025) reporting analyses from the Phase 2 NOVA1 trial of LB-102 in acute schizophrenia.
A post-hoc cognitive analysis showed dose-dependent, statistically significant effect sizes versus placebo at 4 weeks: 0.26 (p=0.0476) at 50 mg, 0.41 (p=0.0027) at 75 mg and 0.66 (p=0.0018) at 100 mg in a completer population. Additional posters cover primary NOVA1 efficacy/safety results and a post-hoc analysis on negative symptoms. Posters go live on the company website on Oct 11, 2025.
LB Pharmaceuticals (NASDAQ:LBRX) has strengthened its Board of Directors with two strategic appointments following its IPO on September 10, 2025. The company has added William Kane, current President and CEO of Uniquity Bio with extensive commercialization experience, and Rekha Hemrajani, who brings significant financial and operational expertise.
These appointments come at a crucial time as LB Pharmaceuticals prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026. LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB Pharmaceuticals (NASDAQ:LBRX) has announced the pricing of its upsized initial public offering, offering 19,000,000 shares of common stock at $15.00 per share. The company expects to raise $285.0 million in gross proceeds before deducting underwriting costs and other expenses.
The IPO includes a 30-day option for underwriters to purchase up to 2,850,000 additional shares. Trading is set to commence on the Nasdaq Global Market on September 11, 2025, under the ticker symbol "LBRX". The offering is expected to close on September 12, 2025, with Leerink Partners, Piper Sandler, and Stifel serving as joint bookrunning managers.